Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 14/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.61 |
| ▸ | GAA | P10253 | 10/20 | 0.61 |
| ▸ | HPGD | P15428 | 8/20 | 0.61 |
| ▸ | GLA | P06280 | 6/20 | 0.61 |
| ▸ | CASP1 | P29466 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6086511 | 0.84 | KDM4E (0.65) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL25857451 | 0.82 | KDM4E (0.45) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL4010310 | 0.81 | KDM4E (0.62) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL6935038 | 0.78 | KDM4E (0.69) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL27762198 | 0.78 | MAPT (0.63) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL6086547 | 0.76 | KDM4E (0.59) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL68892 | 0.75 | MAPT (0.69) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL6604268 | 0.75 | MAOB (0.82) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL1821389 | 0.74 | MAPT (0.71) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL1146916 | 0.74 | MAPT (1.00) | KDM4EALDH1A1GAAHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | KDM4E 2644/4885ALDH1A1 2583/4885GAA 3859/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | KDM4E 2644/4885ALDH1A1 2583/4885GAA 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.